Pharmacodynamics(PD) study of Arbekacin Sulfate in Epithelial Lining Fluid (ELF), an open-label study.

Trial Profile

Pharmacodynamics(PD) study of Arbekacin Sulfate in Epithelial Lining Fluid (ELF), an open-label study.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2016

At a glance

  • Drugs Arbekacin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 12 May 2012 Planned end date (Nov 2012) added as reported by University Hospital Medical Information Network - Japan record.
    • 02 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top